Aurinia Pharmaceuticals Inc
For the period ended Dec 31, 2023. Filed Feb 15, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 15, 2024
AUPH$16.62+1.0%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Shareholders' Equity
AURINIA PHARMACEUTICALS INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY
| Common Shares · Additional Paid-In Capital · AccumulatedOther Comprehensive Loss · Accumulated Deficit · Total Shareholders' Equity | ||||||
|---|---|---|---|---|---|---|
| (in thousands) · Shares · Amount | ||||||
| Balance - January 1, 2021 | 126,725 | $944,328 | $39,383 | $(805) | $(575,156) | $407,750 |
| Issuance of common shares upon public offerings, net of issuance costs | 10,166 | 196,740 | — | — | — | 196,740 |
| Exercise of warrants | 1,434 | 2,102 | (1,737) | — | — | 365 |
| Shares issued on exercise of stock options | 3,238 | 33,073 | (9,652) | — | — | 23,421 |
| Issuance of common shares in conjunction with ESPP program | 37 | 808 | (223) | — | — | 585 |
| Share-based compensation | — | — | 31,243 | — | — | 31,243 |
| Unrealized loss on available-for-sale securities, net | — | — | — | (47) | — | (47) |
| Net loss | — | — | — | — | (180,966) | (180,966) |
| Balance at December 31, 2021 | 141,600 | $1,177,051 | $59,014 | $(852) | $(756,122) | $479,091 |
| Shares issued on exercise of stock options and vesting of performance awards and restricted stock units | 383 | 5,064 | (4,543) | — | — | 521 |
| Issuance of common shares in conjunction with ESPP program | 285 | 3,194 | (1,282) | — | — | 1,912 |
| Share-based compensation | — | — | 32,300 | — | — | 32,300 |
| Unrealized loss on available-for-sale securities, net | — | — | — | (209) | — | (209) |
| Net loss | — | — | — | — | (108,180) | (108,180) |
| Balance at December 31, 2022 | 142,268 | $1,185,309 | $85,489 | $(1,061) | $(864,302) | $405,435 |
| Shares issued on exercise of stock options and vesting of restricted stock units | 1,146 | 11,256 | (8,209) | — | — | 3,047 |
| Issuance of common shares in conjunction with ESPP program | 419 | 3,653 | (1,803) | — | — | 1,850 |
| Share-based compensation | — | — | 45,311 | — | — | 45,311 |
| Unrealized loss on available-for-sale securities, net | — | — | — | 331 | — | 331 |
| Net loss | — | — | — | — | (78,020) | (78,020) |
| Balance at December 31, 2023 | 143,833 | $1,200,218 | $120,788 | $(730) | $(942,322) | $377,954 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.